Janssen Presents Results of Nipocalimab (M281) in P-II Vivacity-MG Study for Adults with Generalized Myasthenia Gravis at AAN2021

 Janssen Presents Results of Nipocalimab (M281) in P-II Vivacity-MG Study for Adults with Generalized Myasthenia Gravis at AAN2021

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Shots:

  • The P-II Vivacity-MG study involves assessing the safety, tolerability, efficacy, PK, PD, and immunogenicity of nipocalimab in addition to SoC vs PBO in a ratio (1:1:1:1:1) in 68 patients with gMG
  • The 1EPs of the study include safety, tolerability, and efficacy assessed by (MG-ADL) ADL score. The 2EPs includes the efficacy as measured by changes in QMG score and revised MG-QoL15 scale from baseline, PK, and PD activity as measured by effects on total serum IgG concentrations, safety and tolerability
  • Nipocalimab is a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn mAb and has been received ODD from US FDA for MG

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Michigan Health Blog

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post